Clinical Trials Browser

Phase 1 × INDUSTRY × obinutuzumab × Clear all

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Phase 1 Recruiting

Lymphoma, B-Cell

NCT06624085 2026-03-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

Lymphoma

NCT05169515 2026-02-23

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT07107490 2026-02-06

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Phase 1 Recruiting

Extensive Stage Small Cell Lung Cancer

NCT06291220 2026-01-08

453 Ph1 CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Phase 1 Active not recruiting

Part1: Advanced B-cell Malignancies

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Phase 1 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04826003 2025-07-14

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06351527 2025-06-19

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Phase 1 Recruiting

Mature B-cell Malignancies

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Phase 1 Terminated

203 enrolled 43 charts

B-cell Malignancies

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Terminated

Lymphoma, Recurrence

NCT04277637 2025-02-17

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Phase 1 Active not recruiting

Mature B-Cell Malignancies

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Phase 1 Completed

119 enrolled 34 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT05219513 2024-08-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1 Terminated

Lymphoma, Non-Hodgkin

NCT03866239 2024-08-09

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Phase 1 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT04434196 2024-07-25

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04313608 2024-03-25

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Phase 1 Completed

23 enrolled 17 charts

Lymphoma, B-Cell

NCT04657302 2024-01-19

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

Lymphoma

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT02417285 2023-10-23

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Phase 1 Completed

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04551352 2022-10-03

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02336048 2021-04-08

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01671904 2020-10-14

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03539484 2020-09-03

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Phase 1 Terminated

26 enrolled 30 charts

Other solid neoplasm

Solid Tumors

NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Solid Cancers

NCT02220842 2020-01-27

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Phase 1 Completed

Lymphoma

NCT01685892 2020-01-10

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02100852 2019-10-02

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02453087 2019-08-29

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT03369964 2018-04-05

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Non-Hodgkin

NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Phase 1 Completed

48 enrolled 27 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse